Literature DB >> 19157504

Prognostic value of apoptosis-related markers in urothelial cancer of the upper urinary tract.

In Gab Jeong1, Sung Han Kim, Hwang Gyun Jeon, Baek Hee Kim, Kyung Chul Moon, Sang Eun Lee, Eunsik Lee.   

Abstract

We investigated the expression of apoptosis-related markers and their association with the clinical outcomes of patients with urothelial carcinoma of the upper urinary tract. A total of 112 patients with urothelial carcinoma of the upper urinary tract that had surgery from March 1998 to July 2005 were included in the study. Tissue microarray slides were used for immunohistochemistry, and immunohistochemical staining was performed to investigate the association of apoptosis-related markers with clinical outcome. Apoptosis was confirmed by the TdT-mediated DUTP nick-end labeling method to obtain the apoptotic index. Survival analysis was performed according to the Kaplan-Meier method, and the Cox proportional hazard regression model was used to compare the relative influence of different prognostic factors. Among the 112 patients, 32 (28.6%) had altered expression of p53, 30 (26.8%) of bcl-2, 62 (55.4%) of bax, 27 (24.1%) of caspase-3, and 23 (20.5%) of survivin. The expression of p53 and caspase-3 was associated with the pathologic grade (P = .035 and P = .004, respectively). Altered expression of caspase-3 was associated with the pathologic stage (P = .016). The multivariate analysis showed that the expression of survivin (hazard ratio 2.91, 95% confidence interval 1.07-7.90, P = .036) and the apoptotic index (AI) (3.35, 1.06-10.56, P = .039), as well as the T and N stages (P = .043 and P = .010, respectively) were significantly associated with the disease-specific survival. Our results suggest that survivin expression and a high apoptotic index were poor prognostic factors for survival in patients with urothelial carcinoma of the upper urinary tract. These results may help to identify a subset of patients who require adjuvant therapy or closer follow-up.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19157504     DOI: 10.1016/j.humpath.2008.10.010

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  10 in total

Review 1.  Expression of p53 in upper urinary tract urothelial carcinoma.

Authors:  Stephen Mitchell; Erik Mayer; Anup Patel
Journal:  Nat Rev Urol       Date:  2011-08-02       Impact factor: 14.432

Review 2.  Distinct patterns and behaviour of urothelial carcinoma with respect to anatomical location: how molecular biomarkers can augment clinico-pathological predictors in upper urinary tract tumours.

Authors:  David R Yates; James W F Catto
Journal:  World J Urol       Date:  2012-09-18       Impact factor: 4.226

Review 3.  Prognostic Genetic Signatures in Upper Tract Urothelial Carcinoma.

Authors:  Qiang Li; Aditya Bagrodia; Eugene K Cha; Jonathan A Coleman
Journal:  Curr Urol Rep       Date:  2016-02       Impact factor: 3.092

4.  Nuclear, but not cytoplasmic, localization of survivin as a negative prognostic factor for survival in upper urinary tract urothelial carcinoma.

Authors:  Hiroshi Kitamura; Toshihiko Torigoe; Yoshihiko Hirohashi; Hiroko Asanuma; Ryuta Inoue; Sachiyo Nishida; Toshiaki Tanaka; Naoya Masumori; Noriyuki Sato; Taiji Tsukamoto
Journal:  Virchows Arch       Date:  2012-11-20       Impact factor: 4.064

5.  Pro- and antiapoptotic markers in upper tract urothelial carcinoma associated with Balkan endemic nephropathy.

Authors:  Ljubinka Jankovic-Velickovic; Slavica Stojnev; Ana Ristic-Petrovic; Zana Dolicanin; Takanori Hattori; Kenichi Mukaisho; Mariola Stojanovic; Vladisav Stefanovic
Journal:  ScientificWorldJournal       Date:  2011-10-17

6.  Alternating expression levels of WWOX tumor suppressor and cancer-related genes in patients with bladder cancer.

Authors:  Elżbieta Płuciennik; Magdalena Nowakowska; Anna Stępien; Mateusz Wołkowicz; Adam Stawiński; Waldemar Różański; Marek Lipiński; Andrzej K Bednarek
Journal:  Oncol Lett       Date:  2014-08-22       Impact factor: 2.967

Review 7.  Tissue-based molecular markers in upper tract urothelial carcinoma and their prognostic implications.

Authors:  Ricardo L Favaretto; Stênio C Zequi; Renato A R Oliveira; Thiago Santana; Walter H Costa; Isabela W Cunha; Gustavo C Guimarães
Journal:  Int Braz J Urol       Date:  2018 Jan-Feb       Impact factor: 1.541

8.  Prognostic significance of Bcl-xL expression and efficacy of Bcl-xL targeting therapy in urothelial carcinoma.

Authors:  S Yoshimine; E Kikuchi; T Kosaka; S Mikami; A Miyajima; Y Okada; M Oya
Journal:  Br J Cancer       Date:  2013-05-14       Impact factor: 7.640

9.  Thrombospondin-1-derived 4N1K peptide expression is negatively associated with malignant aggressiveness and prognosis in urothelial carcinoma of the upper urinary tract.

Authors:  Yasuyoshi Miyata; Shin-ichi Watanabe; Hiroshi Kanetake; Hideki Sakai
Journal:  BMC Cancer       Date:  2012-08-28       Impact factor: 4.430

10.  Diagnostic and prognostic role of BTA, NMP22, survivin and cytology in urothelial carcinoma.

Authors:  Yu-Wen Gong; Yi-Ran Wang; Guang-Rui Fan; Qian Niu; You-Li Zhao; Hanzhang Wang; Robert Svatek; Ronald Rodriguez; Zhi-Ping Wang
Journal:  Transl Cancer Res       Date:  2021-07       Impact factor: 1.241

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.